ANRS 0176s OPTICOV
Optimisation of antiviral therapy in immunocompromised Covid-19 patients: a randomised factorial controlled strategy trial
Last updated on 27 February 2024
Primary objective
To assess whether (i) a combination antiviral therapy of two DAA (nirmatrelvir/r + remdesivir) and/or (ii) an increase in nirmatrelvir/r duration from 5 to 10 days improves viral efficacy by decreasing the SARS-CoV-2 positivity rate by real time RT-PCR (CT<32) in nasopharyngeal swabs at D10.
Theme
Covid-19
Population
Adults
Status
Recruiting
Sample
Nasopharyngeal swabs, Plasma, Serum
If you wish to access biological samples from this study:
Samples from the ANRS MIE BioBank are made available after the request is approved either by the Scientific Advisory Board if the study is ongoing, or by the Director of the ANRS MIE if the study has been completed.
For all requests, please fill in the form below and send it to the following address biobanque@anrs.fr
You are participating or have participated in this study
On the form above, you will find information on the ancillary studies for which your data/samples will be or may have been re-used if you gave your consent at the time of inclusion.
If you would like to find out more about your participation in a clinical study, please see the section below.
Visit the participant area